| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 19.381 | 14.722 | 14.753 | - | 13.758 | 16.104 | 13.224 | 13.428 | 10.259 | 8.338 |
| Total Income - EUR | 19.381 | 14.788 | 14.844 | - | 13.758 | 16.104 | 13.224 | 13.428 | 10.259 | 8.338 |
| Total Expenses - EUR | 19.085 | 19.621 | 15.331 | - | 11.998 | 13.813 | 11.642 | 12.260 | 10.095 | 9.607 |
| Gross Profit/Loss - EUR | 296 | -4.832 | -487 | - | 1.761 | 2.290 | 1.582 | 1.168 | 164 | -1.269 |
| Net Profit/Loss - EUR | -258 | -5.128 | -636 | - | 1.623 | 2.129 | 1.450 | 1.034 | 61 | -1.271 |
| Employees | 0 | 3 | 2 | - | 2 | 2 | 2 | 0 | 0 | 0 |
Check the financial reports for the company - Viofarm V & T Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 571 | 447 | 208 | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 7.130 | 8.219 | 6.366 | - | 2.262 | 3.522 | 3.954 | 3.225 | 2.534 | 678 |
| Inventories | 5.124 | 4.018 | 3.089 | - | 969 | 1.862 | 2.183 | 1.267 | 1.262 | 625 |
| Receivables | 1.391 | 4.112 | 2.865 | - | 407 | 981 | 875 | 1.264 | 1.260 | 0 |
| Cash | 615 | 89 | 412 | - | 886 | 680 | 895 | 694 | 12 | 53 |
| Shareholders Funds | -13.842 | -18.830 | -19.147 | - | -15.527 | -13.104 | -11.363 | -10.358 | -10.266 | -11.480 |
| Social Capital | 45 | 45 | 44 | - | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 21.544 | 27.516 | 25.741 | - | 17.789 | 16.626 | 15.317 | 13.583 | 12.799 | 12.157 |
| Income in Advance | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4778 - 4778" | |||||||||
| CAEN Financial Year |
4778
|
|||||||||
Comments - Viofarm V & T Srl